JP2020533288A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533288A5
JP2020533288A5 JP2020513331A JP2020513331A JP2020533288A5 JP 2020533288 A5 JP2020533288 A5 JP 2020533288A5 JP 2020513331 A JP2020513331 A JP 2020513331A JP 2020513331 A JP2020513331 A JP 2020513331A JP 2020533288 A5 JP2020533288 A5 JP 2020533288A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heterocycle
inhibitor
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020513331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533288A (ja
JP7292740B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/050018 external-priority patent/WO2019051269A1/en
Publication of JP2020533288A publication Critical patent/JP2020533288A/ja
Publication of JP2020533288A5 publication Critical patent/JP2020533288A5/ja
Priority to JP2023089900A priority Critical patent/JP7607969B2/ja
Application granted granted Critical
Publication of JP7292740B2 publication Critical patent/JP7292740B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020513331A 2017-09-08 2018-09-07 Enpp1阻害剤及びがんの治療のためのそれらの使用 Active JP7292740B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023089900A JP7607969B2 (ja) 2017-09-08 2023-05-31 Enpp1阻害剤及びがんの治療のためのそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556117P 2017-09-08 2017-09-08
US62/556,117 2017-09-08
PCT/US2018/050018 WO2019051269A1 (en) 2017-09-08 2018-09-07 ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023089900A Division JP7607969B2 (ja) 2017-09-08 2023-05-31 Enpp1阻害剤及びがんの治療のためのそれらの使用

Publications (3)

Publication Number Publication Date
JP2020533288A JP2020533288A (ja) 2020-11-19
JP2020533288A5 true JP2020533288A5 (enExample) 2021-10-14
JP7292740B2 JP7292740B2 (ja) 2023-06-19

Family

ID=63714052

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513331A Active JP7292740B2 (ja) 2017-09-08 2018-09-07 Enpp1阻害剤及びがんの治療のためのそれらの使用
JP2023089900A Active JP7607969B2 (ja) 2017-09-08 2023-05-31 Enpp1阻害剤及びがんの治療のためのそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023089900A Active JP7607969B2 (ja) 2017-09-08 2023-05-31 Enpp1阻害剤及びがんの治療のためのそれらの使用

Country Status (18)

Country Link
US (3) US11701371B2 (enExample)
EP (2) EP4327882A3 (enExample)
JP (2) JP7292740B2 (enExample)
KR (2) KR20240151869A (enExample)
CN (2) CN111372587B (enExample)
AU (3) AU2018330188C1 (enExample)
BR (1) BR112020004559A2 (enExample)
CA (1) CA3074268A1 (enExample)
DK (1) DK3678668T3 (enExample)
EA (1) EA202090595A1 (enExample)
ES (1) ES2975183T3 (enExample)
HU (1) HUE066413T2 (enExample)
IL (3) IL311010A (enExample)
MA (1) MA50082A (enExample)
MX (2) MX2020002646A (enExample)
PL (1) PL3678668T3 (enExample)
SG (1) SG11202001728YA (enExample)
WO (1) WO2019051269A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3902787A4 (en) * 2018-12-28 2022-12-28 Riboscience LLC Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
HUE064377T2 (hu) 2019-04-12 2024-03-28 Riboscience Llc Biciklusos heteroaril-származékok mint ektonukleotid pirofoszfatáz foszfodiészteráz 1 inhibitorok
US20230002387A1 (en) 2019-09-16 2023-01-05 Aten Porus Lifesciences Pvt. Ltd. 2-amino-s6-substituted thiopurine compounds as inhibitors of the enpp1 protein
CN116574099A (zh) * 2019-09-23 2023-08-11 南京征祥医药有限公司 磷酸二酯酶抑制剂及用途
BR112022014981A2 (pt) * 2020-02-04 2022-09-27 Stingray Therapeutics Inc Inibidores de ectonucleotídeo pirofosfatase/fosfodiesterase 1 (enpp1) e métodos de uso dos mesmos
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4106876B1 (en) 2020-02-18 2025-09-17 Gilead Sciences, Inc. Antiviral compounds
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
WO2021203772A1 (en) * 2020-04-09 2021-10-14 Betta Pharmaceuticals Co., Ltd Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof
US11834512B2 (en) * 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
WO2021225969A1 (en) * 2020-05-04 2021-11-11 Volastra Therapeutics, Inc. Imino sulfanone inhibitors of enpp1
US20230159469A1 (en) 2020-05-08 2023-05-25 Txinno Bioscience Inc. Novel phthalazine derivative having ectonucloeotide pyrophosphatase/phosphodieste rase inhibitory activity, and use thereof
KR102682428B1 (ko) 2020-05-08 2024-07-05 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도
WO2021257614A1 (en) * 2020-06-16 2021-12-23 Volastra Therapeutics, Inc. Heterocyclic inhibitors of enpp1
CN116234802A (zh) 2020-09-03 2023-06-06 免疫传感器治疗股份有限公司 喹啉cgas拮抗剂化合物
CA3200318A1 (en) * 2020-10-30 2022-05-05 1Cbio, Inc. Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof
KR20230118602A (ko) * 2020-12-09 2023-08-11 스팅레이 테라퓨릭스, 인크. Enpp1 및 cdnp의 억제제로서의 포스포네이트
CN116600813A (zh) * 2020-12-09 2023-08-15 斯汀格瑞治疗股份有限公司 作为enpp1和cdnp抑制剂的膦酸盐
KR102720206B1 (ko) 2020-12-29 2024-10-21 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도
WO2022146022A1 (ko) 2020-12-29 2022-07-07 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도
KR102686866B1 (ko) 2021-01-29 2024-07-19 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도
US20240116882A1 (en) 2021-01-29 2024-04-11 Txinno Bioscience Inc. Novel benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof
WO2022197734A1 (en) * 2021-03-16 2022-09-22 Riboscience Llc Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
KR102923359B1 (ko) 2021-04-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
CN115536696B (zh) * 2021-06-29 2023-07-14 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
EP4395786A4 (en) * 2021-09-03 2025-07-23 Angarus Therapeutics Inc ENPP1 INHIBITORS AND IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS
EP4422639A4 (en) * 2021-10-29 2025-09-03 Angarus Therapeutics Inc ENPP1 INHIBITORS AS METASTASIS INHIBITORS
KR20250004639A (ko) 2022-03-02 2025-01-08 이뮨센서 테라퓨틱스, 인코포레이티드 퀴놀린 cGAS 길항제 화합물
CN118488950A (zh) * 2022-04-11 2024-08-13 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
US20230346771A1 (en) 2022-04-29 2023-11-02 Petragen, Inc. Inhibitors of enpp1 and modulation of bone growth
CN114767863B (zh) * 2022-04-29 2024-01-30 西北工业大学 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用
JP2025527243A (ja) * 2022-08-01 2025-08-20 スラバティ エーアイ テクノロジー プライベート リミテッド 新規なエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ1(enpp-1)阻害剤およびその使用
CN120981233A (zh) * 2023-04-11 2025-11-18 香港科技大学 由新型enpp1抑制剂使轴突再生
WO2024216211A2 (en) * 2023-04-14 2024-10-17 The Board Of Trustees Of The Leland Stanford Junior University Methods of inhibiting tumor progression and metastasis by inhibition of enpp1
CN118108720B (zh) * 2023-12-28 2026-03-10 河南大学 一种苝酰亚胺衍生物pdic-ns及应用
WO2025207514A1 (en) * 2024-03-25 2025-10-02 Riboscience Llc Bicyclic heteroaryl sulfanediimine derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA228044A (en) 1923-01-16 Thomas Noble Boughton Die for forming bolts
CA190896A (en) 1919-02-24 1919-06-17 Josephat C. Bergeron Advertising device
DE3319795A1 (de) 1983-06-01 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von phosphonsaeureestern
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
AU704973B2 (en) 1995-04-21 1999-05-13 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
AU2002254152A1 (en) 2001-03-08 2002-09-24 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
US20040101840A1 (en) * 2001-04-27 2004-05-27 Chung Leland W.K. Identification, cloning and characterization of a novel pc-1 gene differentially expressed in prostate cells and tissues
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
PT1847539E (pt) 2002-12-24 2009-10-06 Astrazeneca Ab Derivados de quinazolina
US20070004763A1 (en) 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2621923B1 (en) 2010-09-29 2017-03-29 Intervet International B.V. N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア I型インターフェロンの環状ジヌクレオチド誘導法
ES2754269T3 (es) 2013-05-18 2020-04-16 Aduro Biotech Inc Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
AU2015321654B2 (en) * 2014-09-22 2019-10-31 National Health Research Institutes Heterocyclic compounds and use thereof
WO2016049568A1 (en) * 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
CN105153153A (zh) 2015-08-31 2015-12-16 吉林奥来德光电材料股份有限公司 一种新的芳香族胺类化合物及其制备与应用
TWI659949B (zh) 2016-05-16 2019-05-21 臺北醫學大學 組蛋白去乙醯酶6抑制劑及其用途
WO2018119325A1 (en) 2016-12-22 2018-06-28 Mavupharma, Inc. Compositions and methods of enhancing or augmenting type i ifn production
WO2018127928A1 (en) 2017-01-09 2018-07-12 The Australian National University Synergists for improved pesticides
US10518257B2 (en) 2017-05-04 2019-12-31 Exxonmobil Research And Engineering Company Metal organic frameworks, their synthesis and use
WO2018229139A1 (en) 2017-06-14 2018-12-20 Fundación Para La Investigación Médica Aplicada Novel compounds for use in cancer
CN111315723A (zh) 2017-08-31 2020-06-19 艾伯维公司 膜外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制剂及其用途
MA54879A (fr) 2019-02-01 2021-12-08 Univ Leland Stanford Junior Inhibiteurs d'enpp1 et méthodes de modulation de réponse immunitaire
CN114437128B (zh) * 2022-01-28 2023-12-19 中国科学院长春应用化学研究所 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用

Similar Documents

Publication Publication Date Title
JP2020533288A5 (enExample)
KR102505664B1 (ko) Ezh2 저해제 및 e3 리가제 바인더를 포함하는 화합물 및 이를 유효성분으로 함유하는 ezh2 관련 질환의 예방 또는 치료용 약학적 조성물
IL272948B2 (en) enpp1 inhibitors and their use for cancer treatment
KR101629356B1 (ko) 퀴나졸리논 유도체의 제조방법
US11248012B2 (en) Phospholipidation of imidazoquinolines and oxoadenines
KR101414931B1 (ko) 아실티오우레아 화합물 또는 그 염 및 그 용도
JP2022541467A (ja) オーロラキナーゼ阻害剤およびその使用
KR20170049604A (ko) Bub1 억제제로서의 벤질 치환된 인다졸
JP2018513876A (ja) Dnaアルキル化剤
JP2018520109A (ja) ピリド−アザヘテロサイクリック化合物及びその製造方法と用途
JP2010513494A5 (enExample)
JP2016512823A5 (enExample)
EP2855454A1 (en) Synthesis of antiviral compound
EA034922B1 (ru) Соединения и их применения для модуляции гемоглобина
JP2011506588A5 (enExample)
JP7627008B2 (ja) ピロール化合物
WO2009121535A2 (en) Antiproliferative compounds and therapeutic uses thereof
JP2015518011A (ja) ピロロ[2,1−f][1,2,4]トリアジン誘導体およびその抗腫瘍用途
FR3008978A1 (fr) "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
JP2022527306A (ja) Stingアゴニストとしての大環状化合物
JP2024530111A (ja) アフィカムテンを調製するための工程
AU2006213769B2 (en) Process for preparing 2,3-disubstituted indoles
JP2013530130A (ja) ヘテロアリール(アルキル)ジチオカルバメート化合物、その調製方法及び使用
CN109134481B (zh) 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
RS59787B1 (sr) Novo heterociklično jedinjenje, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto